DCB stands for drug-coated balloon, a type of medical device used during angioplasty to treat narrowed or blocked arteries. Unlike a traditional balloon that simply pushes plaque aside, a DCB is coated with an antiproliferative drug that transfers directly into the artery wall during inflation, helping prevent the artery from narrowing again. The key advantage: it delivers medication without leaving a permanent implant behind.
How a Drug-Coated Balloon Works
A DCB looks and functions much like a standard angioplasty balloon, with one critical difference. Its surface is coated with a thin layer of medication, most commonly paclitaxel, at a typical dose of about 2 micrograms per square millimeter. When the balloon is inflated inside a narrowed artery, the pressure pushes the drug coating into the vessel wall. The entire transfer happens in under a minute of contact time, usually at least 30 to 60 seconds of inflation depending on the technique used.
The drug works by slowing down the excessive cell growth that causes arteries to re-narrow after treatment, a problem called restenosis. Once the medication is embedded in the tissue, the balloon is deflated and removed entirely. Nothing stays behind in the artery. This is often called the “leave nothing behind” strategy, and it stands in direct contrast to drug-eluting stents, which are permanent metal scaffolds that release medication slowly over weeks or months.
Imaging studies show the drug tends to lodge within grooves and small cracks on the inner surface of the artery. Higher inflation pressures push the coating deeper into the tissue, which improves how well the drug sticks and how long it remains effective.
When DCBs Are Used
The most established use of DCBs is treating in-stent restenosis, which is when an artery narrows again inside a previously placed stent. European cardiology guidelines have recommended DCBs as a top-tier option for this problem, on equal footing with placing a new drug-eluting stent. The logic is straightforward: if a stent has already failed, adding another metal layer on top of it isn’t always the best answer.
DCBs are particularly well suited to situations where stents are problematic. These include:
- Small vessels where a stent may not fit well or could restrict blood flow
- Arteries near major branch points where a stent could block a side branch
- Patients who already have multiple stent layers and adding more metal increases risk
- Long, diffuse lesions that would require an impractically long stent
Beyond the coronary arteries of the heart, DCBs are also widely used in the legs. Peripheral artery disease, particularly in the upper leg arteries, is the third most common form of atherosclerosis-related illness. DCBs work well for medium-length blockages with minimal calcification in these vessels, while heavily calcified lesions may still need a stent.
Preparing the Artery Before a DCB
A DCB can’t simply be inserted into a severely blocked artery. The vessel needs to be opened first with a standard balloon, a process called predilatation. This step is critical because the drug coating can only transfer effectively if it makes good, even contact with the artery wall.
International consensus guidelines define successful preparation as meeting three criteria: no significant tears in the vessel lining that restrict blood flow, residual narrowing of 30% or less, and adequate blood flow confirmed by pressure measurements. If the artery isn’t adequately prepared, the drug won’t distribute evenly and the treatment is less likely to succeed. In some cases, specialized cutting balloons are used instead of standard balloons to achieve a cleaner result before the DCB is deployed.
DCB vs. Drug-Eluting Stents
Drug-eluting stents have been the default treatment for blocked coronary arteries for years, and they remain excellent devices. But they come with inherent tradeoffs. A stent is a permanent metal cage that stays in the artery forever, which can impair the vessel’s natural ability to expand and contract. It also requires the patient to take blood-thinning medications for an extended period to prevent clots from forming on the metal surface.
DCBs avoid these issues entirely. Because nothing is left behind, the artery retains its normal movement and flexibility. There’s no foreign body to trigger clot formation or chronic inflammation. Clinical studies comparing the two approaches for in-stent restenosis have found similar outcomes, which is notable because it means DCBs can match stent performance without the long-term presence of an implant. One study tracking patients after DCB treatment for new coronary blockages found that only about 5% needed a repeat procedure on the same spot during follow-up.
That said, DCBs aren’t universally better. For certain types of blockages, particularly heavily calcified or very complex lesions, stents still provide structural support that a balloon alone cannot. The choice between the two depends heavily on the specific anatomy and clinical situation.
Safety of Paclitaxel-Coated Devices
In 2018, a widely publicized analysis suggested that paclitaxel-coated devices used in leg arteries might be associated with higher death rates after two years. This triggered significant concern among patients and physicians. The FDA launched a thorough review that included updated data from randomized trials with follow-up ranging from two to five years, along with several large real-world studies covering tens of thousands of patients.
The conclusion: the data does not support an excess mortality risk from paclitaxel-coated devices. The FDA reviewed results from multiple independent sources, including a large Swedish clinical trial, a U.S. Veterans Health Administration database study, and a Medicare analysis. None found a late mortality signal. The agency has since worked with manufacturers to update product labeling to reflect this finding.
What the Procedure Feels Like
From a patient’s perspective, a DCB procedure is virtually identical to standard balloon angioplasty. It’s performed through a small puncture in the wrist or groin, using a thin catheter threaded to the blocked artery under X-ray guidance. The balloon inflation may cause brief chest pressure or discomfort in the affected area, lasting only the 30 to 60 seconds the balloon is expanded. Most patients are awake with light sedation throughout.
Recovery is generally quick. Because no stent is implanted, the duration of required blood-thinning medication may be shorter than after stent placement, though your cardiologist will tailor this based on your overall risk profile. The treated artery is monitored with follow-up imaging or stress testing to confirm it remains open.